<DOC>
	<DOCNO>NCT02727231</DOCNO>
	<brief_summary>The main objective study determine whether day night closed-loop insulin delivery 4 week free living condition superior usual insulin pump therapy adult type 1 diabetes HbA1C &lt; 7.5 % . This open-label , multi center , randomize , crossover design study , involve 2-4 week run-in period , follow two 4 week study period glucose level control either automate day- night closed-loop system subject usual insulin pump therapy random order . A total 34 adult ( aim 24 completed subject ) age 18 year old T1D insulin pump therapy HbA1C &lt; 7.5 % recruit diabetes clinic establish method participate center . Subjects receive appropriate training safe use closed-loop insulin delivery system . Subjects regular contact study team home study phase include 24/7 telephone support . The primary outcome time spend target range 3.9 10.0 mmol/L record CGM home stay . Secondary outcome time spend glucose level target , record CGM , CGM-based metric .</brief_summary>
	<brief_title>Closing Loop Adults With Type 1 Diabetes HbA1C &lt; 7.5 % Under Free Living Conditions</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<criteria>The subject type 1 diabetes define WHO The subject 18 year age older The subject insulin pump least 6 month good knowledge insulin selfadjustment include carbohydrate count The subject treat one rapid act insulin analogue ( Insulin Aspart , Insulin Lispro Insulin Glulisine ) HbA1c &lt; 7.5 % ( 58mmol/mmol ) base analysis central laboratory equivalent The subject willing perform regular fingerprick blood glucose monitoring , least 6 measurement per day The subject willing wear closedloop system home work place The subject willing follow study specific instruction The subject willing upload pump CGM data regular interval Female subject child bear age effective contraception must negative urineHCG pregnancy test screening . Nontype 1 diabetes mellitus Any physical psychological disease condition likely interfere normal conduct study interpretation study result Current treatment drug know significant interference glucose metabolism , systemic corticosteroid , judge investigator Known suspect allergy insulin Subjects clinically significant nephropathy , neuropathy proliferative retinopathy judge investigator Significantly reduce hypoglycaemia awareness judge investigator More one episode severe hypoglycaemia define American Diabetes Association precede 6 month ( Severe hypoglycaemia define event require assistance another person actively administer carbohydrate , glucagon , take corrective action ) . Random Cpeptide &gt; 100pmol/l concomitant plasma glucose &gt; 4 mM ( 72 mg/dl ) Total daily insulin dose &gt; 2 IU/kg/day Subject pregnant breast feed plan pregnancy near future ( within next 3 month ) Severe visual impairment Severe hear impairment Subjects use implanted internal pacemaker Lack reliable telephone facility contact Subject proficient English ( UK ) German ( Austria ) Subjects live alone Additional exclusion criterion specific Austria : Positive result urine drug screen ( amphetamines/metamphetamines , barbiturate , benzodiazepine , cannabinoids , cocaine , opiates ) . Additional exclusion criterion specific Austria : Positive alcohol breath test .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>closed loop glucose control</keyword>
	<keyword>hypoglycemia</keyword>
	<keyword>type 1 diabetes</keyword>
	<keyword>HbA1C &lt; 7.5 %</keyword>
</DOC>